Xinjiang Huakang Pharmaceutical

Xinjiang Huakang Pharmaceutical is a China-based pharmaceutical company specializing in the research, development, and manufacturing of Traditional Chinese Medicine (TCM) and modern pharmaceutical products. Headquartered in Urumqi, the company is a leader in the modernization of ethnic medicines native to the Xinjiang region, particularly those derived from Uyghur traditional practices. Its flagship product line, the Yizhihao series, is widely recognized in China for treating respiratory conditions such as influenza and the common cold. The company operates multiple GMP-certified production lines for various dosage forms, including granules, tablets, and capsules. Xinjiang Huakang is listed on the National Equities Exchange and Quotations (NEEQ) and maintains a significant market presence in Northwest China.